It'll eventually explode up 5-8 days in a row
Hence the 6 month delay, 333 happened 6 months ago And it missed the target. So they've been hiding material information so they could dump more options, but I guess they lucked out the FDA may be willing to play ball.
Wow, did you think of that on your own? Take the information with a grain of salt, but I've been spot-on quite a few times. Make money, lose money, I don't care, but Link blatantly takes advantage of the market to line his and his friends pockets. Just remember this, if Newlink has a huge shelf trade prior to 2nd interim it will confirm they already know that results will have to wait until 444.
Currently NLNK is overbought with no catalyst until links next leak for the day after March options expiration.
So the investigation of pershing and greenberg is under way!?!
What a #$%$, told all his friends no to expect a decision in March. The complete collapse in option premiums is telling. I guess he will hold the news for the Monday after options expiration.
If they saw a guarantee with algen they would have already allowed crossovers. The only wildcard is bribe money to keep Newlinks drugs off the market as long as possible.
Trolls, trying to spread fear and uncertainty, they still own the shares, but yahoo reporting is soo soo good. Who cares anyway, it is a binary event, drug works and the stock is worth $230 tomorrow, if it doesn't it is worth $20 until IDO is confirmed or fails.
You can sue ackman now, herbaaaaaaaalifeeeee, you can sue ackman now! He has admitted 28 times that his goal is the deterioration of your business (a proven fact), heeeeerbalife, judges like proven facts. Even if you are an FTC defined pyramid scheme you still have legal standing on suing someone trying directly interfere with your business model. Herbalife, heeeeerbaaalife, herbaaaaaaaalife, this is your brain! Ackman has $20 billion dollars, and yes, his clients are just as liable! Herbalife, heeeerbalife, sue now and ackman doesn't even have enough time to dig into the Financials prior to the FTC's judgement of a $75 million fine for lead generation up until 2013.
The guy is a moron, but money does buy you what ever you want, bribes, NY post articles, tilson fake chatter, Congressmen, CNBC spots, a bunch of boiler room yahoo board posters, racketeering, obstruction of justice, SEC fakery by trading as a market maker. He's like that guy you play poker against that thinks he is good, but he has that obvious tell.
His average is $31 (his own words), his max gain is $600 million (HLF at zero), yet he has $1.5 billion in capital tied up in HLF. Haha about the 40%, a 2 year investment with max gain on investment of 40%, where loses could have been 500% if icahn wasn't a #$%$. BTW, his average is $31 because he was squeezed out of 10 million shares in the $70-80 range, then most of the options he bought were not exercised because he couldn't locate the shares to borrow - if he did exercise them it would have been an epic squeeze.
33.7 million shares exchanged hand on Jan 19, which happened to exactly equal the number of shares short. Don't forget about the dark pools.
Newlink even admitted on their last presentation that death events were under reported. DSMC predicts 444 events by 3rd quarter of 2015, yet it took 12 months to go from 222 to 333.
The FDA granted the drug accelerated approval — more than two months ahead of its April 13 target date — based on a 165-patient study showing that it slowed the progression of breast cancer. Patients taking Ibrance and letrozole lived 20.2 months on average before their tumors worsened. That was about twice as long as the benefit for women in a comparison group who only received letrozole. The study is ongoing and it's not yet clear whether Ibrance's benefits result in increased survival times for patients.
The FDA grants drugs accelerated approval to drugs that show highly promising preliminary results that are expected to result in clinical benefits for patients. If follow-up studies do not confirm those benefits, regulators can revoke the drug's approval. The agency previously named palbociclib a breakthrough therapy, a designation given to medicines for diseases with no or inadequate treatments. It's meant to speed up the testing and approval process.